{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit not estimable","groupId":"OG000","lowerLimit":"0.6","upperLimit":"NA","value":"1.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"PFS is defined as the time from first dosing date to the date of the first documented progression or death due to any cause, whichever occurs first.\n\nProgression is determined per International Myeloma Working Group (IMWG) uniform criteria.\n\nParticipants who die without a reported prior progression were considered to have progressed on the date of their death.\n\nParticipants who did not progress or die were censored on the date of their last evaluable assessment. Participants who did not have any on study efficacy assessments and did not die were censored on the first dosing date.\n\nParticipants who switched to subsequent therapy prior to documented progression were censored on the date of the last evaluable assessment prior to the initiation of the new therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Elotuzumab in combination with Nivolumab in a 28-day cycle.","id":"OG000","title":"EN Cohort"}],"paramType":"MEDIAN","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From first dose to study completion date (up to approximately 50 months)","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}